Hoyoung Huh MD/PhD is a Silicon Valley-based entrepreneur and investor driven by innovative science, creative collaborations and impact investing. Hoyoung is a global leader in healthcare and technology-based businesses, having been involved in formation/growth of over 20 innovative companies. He is the Founder of Hannol Ventures, AntriaBio, Healthcare & Humanity Foundation, a platform for catalytic and transformative giving. Currently, he serves as Chairman/CEO of pH Pharma, Chairman of Geron Corporation (NASDAQ: GERN), CytomX Therapeutics (NASDAQ:CTMX), and Board Director of Shared-X.
Previously, Hoyoung was CEO of BiPar Sciences, Chairman of Epizyme (NASDAQ:EPZM), Board Director of Facet Biotech (NASDAQ:FACT), Nektar Therapeutics (NASDAQ:NKTR), Addex Therapeutics (SWISS:ADDX) and EOS, S.p.A (Milano, Italy). Earlier in his career, Dr. Huh was a Partner at McKinsey & Company, where he was a leader in the healthcare and technology sectors based in Silicon Valley, New York and Asia.
Hoyoung is a frequent speaker on innovation, entrepreneurship and governance, including presentations at the World Economic Forum, Stanford Business School and Cleveland Clinic. His not-for-profit focus include global health/poverty and music, where he served as former board member of SF Jazz, Resurge International and Berklee School of Music.
Hoyoung holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a bachelor’s degree in biochemistry and economics from Dartmouth College, and Certification in Board Governance from Stanford Law School.